Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nadza, Durakovic"'
Autor:
Kelly E. Dooley, Nadza Durakovic, Vera Belitsky, Eric L. Nuermberger, Ekwaro A. Obuku, Carole D. Mitnick
Publikováno v:
Journal of Infectious Diseases. 207:1352-1358
The World Health Organization (WHO) estimates that more than 1.3 million people with multidrug-resistant (MDR) tuberculosis caused by Mycobacterium tuberculosis resistant to isoniazid and rifampin will require treatment in the 27 countries with the h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82953d97410e4edf2d2590037bdfc011
https://doi.org/10.1093/infdis/jis460
https://doi.org/10.1093/infdis/jis460
Autor:
Kelly E, Dooley, Carole D, Mitnick, Mary, Ann DeGroote, Ekwaro, Obuku, Vera, Belitsky, Carol D, Hamilton, Mamodikoe, Makhene, Sarita, Shah, James C M, Brust, Nadza, Durakovic, Eric, Nuermberger, Sonya, Shin
Treatment of drug-resistant tuberculosis is hindered by the high toxicity and poor efficacy of second-line drugs. New compounds must be used together with existing drugs, yet clinical trials to optimize combinations of drugs for drug-resistant tuberc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33cf932fbdc734e1c1b11fa03d62d10e
https://europepmc.org/articles/PMC3520382/
https://europepmc.org/articles/PMC3520382/
Autor:
Carole D. Mitnick, Eric L. Nuermberger, Kelly E. Dooley, Mary Ann DeGroote, Nadza Durakovic, James C.M. Brust, Carol Dukes Hamilton, Mamodikoe Makhene, Ekwaro A. Obuku, Sarita Shah
Publikováno v:
Clinical Infectious Diseases. 56:168-169
To the Editor—We agree with Drs Seddon, Schaaf, and Hesseling that research focused on optimizing the use of second-line drugs for children with drug-resistant tuberculosis is urgently needed [1]. As the authors state, the disease burden and spectr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07734cb42bd2a36dea4b905cf0a5045f
https://doi.org/10.1093/cid/cis820
https://doi.org/10.1093/cid/cis820